Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1

Conditions

Multi-centric Castleman's Disease 2Sarcoma, Kaposi 1Neoplasms 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma 1Lymphadenopathy 1HIV Infections 1Castleman Disease 1Acquired Immunodeficiency Syndrome 1

Interventions

liposomal doxorubicin 2Zidovudine 2Valganciclovir 2tocilizumab 1tanespimycin 1pomalidomide 1ibrutinib 1Vincristine 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Multi-centric Castleman's Disease × Valganciclovir × Clear all
NCT00092222 2026-06-05

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡